TL;DR
This study introduces a novel quantitative top-down proteomics (TDP) approach combining capillary zone electrophoresis (CZE) with mass spectrometry (MS/MS) to analyze human brain proteoforms. They discovered significant differences in protein variants (proteoforms) between healthy and Alzheimer's disease (AD) brains, highlighting the complexity of AD pathogenesis and identifying potential biomarkers.
What Problem Does This Paper Address?
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by cognitive decline and the aggregation of specific proteins like amyloid-beta and tau. Understanding the molecular mechanisms driving AD progression is crucial for developing effective diagnostics and therapies. Traditional proteomics methods (bottom-up proteomics) often lose information about protein variants (proteoforms) due to enzymatic digestion. Proteoforms, arising from alternative splicing, post-translational modifications (PTMs), and other processes, can have distinct biological functions. Therefore, a method that can accurately identify and quantify these intact proteoforms in complex biological samples like the human brain is needed to gain a deeper understanding of AD.
Methods
The researchers developed a two-dimensional (2D) analytical workflow. First, they employed Size Exclusion Chromatography (SEC) to fractionate complex brain tissue lysates based on molecular weight, reducing sample complexity and improving proteome coverage. Following SEC, they utilized Capillary Zone Electrophoresis (CZE) coupled with Tandem Mass Spectrometry (MS/MS) for proteoform identification and quantification. CZE acts as a liquid-phase ion mobility separation technique, separating analytes based on their mobility in an electric field, which is influenced by their mass-to-charge ratio. This CZE-MS/MS approach allows for the analysis of intact proteoforms. The data analysis was performed using the TopPIC pipeline, a specialized software for top-down proteomics, to identify and quantify proteoforms and their abundance differences between AD and control samples.
Datasets
The study analyzed postmortem temporal cortex tissue samples from a small cohort of 5 Alzheimer's disease (AD) patients and 5 age-matched healthy controls. These samples were obtained from the Michigan Alzheimer's Disease Research Center (MADRC) clinical cohort.
Key Insights and Ideas
- Proteoform Heterogeneity is Key: The study strongly suggests that focusing on individual proteoforms, rather than just proteins, is essential for understanding complex diseases like AD. The drastic differences observed at the proteoform level between AD and healthy brains underscore this point.
- CZE-MS/MS as a Powerful Tool: The successful application of CZE-MS/MS for quantitative TDP in human brain tissue demonstrates its potential as a robust platform for analyzing complex proteomes, offering high separation efficiency.
- Bidirectional Regulation of Key AD Genes: The identification of proteoforms from genes known to be involved in AD (e.g., CALM1, MAPT, NRGN) exhibiting opposite expression patterns (upregulated in AD vs. healthy) highlights the intricate regulatory mechanisms at play in disease progression.
- PTMs as Critical Modifiers: The study identified numerous proteoforms with various post-translational modifications (PTMs) like acetylation, phosphorylation, and oxidation, emphasizing their role in altering protein function and contributing to AD pathology.
Key Results
- 3191 Unique Proteoforms Identified: The CZE-MS/MS approach successfully identified a substantial number of unique proteoforms (3191) from 500 proteins.
- Drastic Proteoform Transformation: A significant transformation in the proteoform profile was observed in AD brains compared to healthy controls. Only 736 out of 3191 proteoforms (23%) were common to both groups, with over 2200 proteoforms being unique to either AD or healthy samples.
- 157 Differentially Abundant Proteoforms: Among the shared proteoforms, 157 showed statistically significant abundance differences between AD and control groups.
- Biological Pathway Enrichment: Gene Ontology and pathway analysis of the differentially expressed proteoforms revealed broad changes in biological processes in AD brains, including telomere organization, substantia nigra development, amyloid fibril formation, and microtubule cytoskeleton organization, all highly relevant to AD pathogenesis.
- Specific Proteoform Examples: The study highlighted specific proteoforms, such as those from tau (MAPT), neurogranin (NRGN), and calmodulin-1 (CALM1), showing distinct expression patterns and PTMs in AD. For instance, certain tau proteoforms were found to be condition-specific, and others showed significantly higher abundance in AD.
Limitations and Future Work
- Small Sample Size: The authors acknowledge that a main limitation of this pilot study is the small number of human brain samples analyzed (5 AD and 5 controls).
- Future Expansion: To address this, they plan to expand the study to include more human brain samples, encompassing control, early AD, and potentially late AD subjects. This larger cohort will allow for more robust statistical analysis and a deeper understanding of the proteoform landscape in AD progression.
- Further Functional Studies: While the study identifies potential proteoform biomarkers and therapeutic targets, further functional studies will be necessary to elucidate the precise roles of these specific proteoforms and their PTM combinations in AD pathogenesis.
Summary updated